Cargando…
Has the time to come leave the “watch-and-wait” strategy in newly diagnosed asymptomatic follicular lymphoma patients?
BACKGROUND: Historically, the median overall survival for follicular lymphoma (FL) has been considered to be 9-10 years, and no treatment had ever prolonged this time period. Studies conducted more than 20 years ago demonstrated that treating patients with asymptomatic FL at the onset of the disease...
Autores principales: | Rueda, Antonio, Casanova, María, Redondo, Maximino, Pérez-Ruiz, Elisabeth, Medina-Pérez, Ángeles |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3489567/ https://www.ncbi.nlm.nih.gov/pubmed/22650448 http://dx.doi.org/10.1186/1471-2407-12-210 |
Ejemplares similares
-
Genotype-driven recruitment: a strategy whose time has come?
por: Budin-Ljøsne, Isabelle, et al.
Publicado: (2013) -
The outcome of watchful waiting in patients with previously treated follicular lymphoma
por: Fujino, Takahiro, et al.
Publicado: (2022) -
Watch and Wait Approach for Rectal Cancer
por: Cerdan-Santacruz, Carlos, et al.
Publicado: (2023) -
mHealth and global mental health: still waiting for the mH(2) wedding?
por: Farrington, Conor, et al.
Publicado: (2014) -
Influence of the watch and wait strategy on clinical outcomes of patients with follicular lymphoma in the rituximab era
por: Yuda, Sayako, et al.
Publicado: (2016)